General Information of Drug (ID: DMFNDBC)

Drug Name
Otelixizumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Type-1 diabetes 5A10 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMFNDBC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [3]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [4]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [5]
Talquetamab DMXRENI Multiple myeloma 2A83 Approved [6]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [7]
Nivatrotamab DMAOUZV Small-cell lung cancer 2C25.Y Phase 2 [8]
Plamotamab DMOV28A Diffuse large B-cell lymphoma 2A81 Phase 2 [9]
Odronextamab DMP6NVV B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [10]
Tarlatamab DME33OU Small-cell lung cancer 2C25.Y Phase 2 [11]
TAK-280 DM08RE5 Aggressive cancer 2A00-2F9Z Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8458).
2 Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
5 Clinical pipeline report, company report or official report of Genmab.
6 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
7 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
8 Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
9 Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
10 Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
11 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
12 ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.